Bristol - International Biopharmaceutical Industry

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Subsection - Oncology

Essential DMPK Strategies for IND Success

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

news

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Merck to a notable ...

30 May 2022 news blood | Bristol

Continue Reading →

news

Key Bristol Myers drug holds up in long-term psoriasis study

Dive Brief: An experimental psoriasis drug developed by Bristol Myers Squibb maintained its effectiveness over more than a year of treatment in a clinical trial ex...

13 May 2022 news Bristol | Drug

Continue Reading →

news

Bristol Myers gets FDA decision date for earlier use of CAR-T therapy

Dive Brief: The Food and Drug Administration will decide whether to approve Bristol Myers Squibb's cancer cell therapy Breyanzi for earlier use by late June, the c...